About 5-hydroxytryptamine receptor 1D
5-hydroxytryptamine receptor 1D (HTR1D) is a protein
from Homo sapiens identified by UniProt accession
P28221, 377 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 1D |
| UniProt accession | P28221 |
| Gene | HTR1D |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (109)
Diseases linked to this target (Open Targets).
- migraine disorder · score 0.61
- schizophrenia · score 0.59
- Headache · score 0.57
- migraine with aura · score 0.51
- pain · score 0.51
- migraine without aura · score 0.51
- mental or behavioural disorder · score 0.50
- schizoaffective disorder · score 0.50
- post operative nausea and vomiting · score 0.47
- obesity · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P28221-F1 | alphafold | PREDICTED | 78.96 | — |
Amino-acid sequence (377 residues)
MSPLNQSAEG LPQEASNRSL NATETSEAWD PRTLQALKIS LAVVLSVITL ATVLSNAFVL TTILLTRKLH TPANYLIGSL ATTDLLVSIL VMPISIAYTI THTWNFGQIL CDIWLSSDIT CCTASILHLC VIALDRYWAI TDALEYSKRR TAGHAATMIA IVWAISICIS IPPLFWRQAK AQEEMSDCLV NTSQISYTIY STCGAFYIPS VLLIILYGRI YRAARNRILN PPSLYGKRFT TAHLITGSAG SSLCSLNSSL HEGHSHSAGS PLFFNHVKIK LADSALERKR ISAARERKAT KILGIILGAF IICWLPFFVV SLVLPICRDS CWIHPALFDF FTWLGYLNSL INPIIYTVFN EEFRQAFQKI VPFRKAS
Explore 5-hydroxytryptamine receptor 1D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets